Loading clinical trials...
Loading clinical trials...
Effects of Intrathecal Midazolam (1mg) With Hyperbaric Bupivacaine 0.5% (15mg) for Spinal Anesthesia for Caesarean Section
This study evaluates the effects of intrathecal midazolam (1 mg) combined with hyperbaric bupivacaine 0.5% (15 mg) for spinal anesthesia in cesarean section patients.
The addition of midazolam, a benzodiazepine with analgesic and anxiolytic properties to bupivacaine is hypothesized to enhance the quality of anesthesia and postoperative pain relief without significant side effects. A comparative analysis was conducted to assess sensory and motor block characteristics, postoperative analgesia duration, maternal hemodynamic stability, and neonatal outcomes.
Age
18 - 40 years
Sex
FEMALE
Healthy Volunteers
Yes
Nowshera
Nowshera, Khyber Pakhtunkhwa, Pakistan
Start Date
February 28, 2024
Primary Completion Date
July 1, 2024
Completion Date
March 1, 2025
Last Updated
December 27, 2024
64
ACTUAL participants
group 1
DIAGNOSTIC_TEST
Lead Sponsor
Superior University
NCT04307069
NCT07192718
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07229222